Timothy Brooks, DO
Family Medicine · Clarion, PANPI 1558365189
Payments from drug & device makers
Across 135 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$205
- Lilly USA, LLC$199
- AbbVie$184
- Abbott$133
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
- Boehringer Ingelheim$97
- plus $881 from 21 others
What the payments were for
- Food & beverage$1,816100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $205 |
| Lilly USA, LLC | 12 | $199 |
| AbbVie(2 entities) | 13 | $184 |
| Abbott | 8 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $125 |
| Boehringer Ingelheim | 8 | $97 |
| AstraZeneca | 6 | $91 |
| Johnson & Johnson | 6 | $74 |
| Sanofi-aventis U.S. LLC | 5 | $69 |
| Novo Nordisk | 4 | $65 |
| Pfizer | 4 | $64 |
| Sunovion Pharmaceuticals Inc. | 4 | $57 |
| Amgen | 3 | $49 |
| Verona Pharma, Inc. | 2 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Novartis | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $34 |
| Exact Sciences | 2 | $32 |
| GSK | 2 | $30 |
| Alkermes, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$1,823 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $158,227 |
| EliquisApixaban | 125 | $96,522 |
| XareltoRivaroxaban | 102 | $86,587 |
| JardianceEmpagliflozin | 89 | $82,477 |
| TrulicityDulaglutide | 61 | $63,193 |
| RybelsusSemaglutide | 48 | $62,225 |
| FarxigaDapagliflozin Propanediol | 78 | $54,624 |
| MounjaroTirzepatide | 27 | $31,672 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $29,215 |
| MyrbetriqMirabegron | 45 | $27,068 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $26,250 |
| EntrestoSacubitril/Valsartan | 34 | $22,804 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,101 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,831 |
| PremarinEstrogens, Conjugated | 42 | $14,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $65 | $220,452220 claims |
| PfizerEliquis, Premarin | $64 | $110,802167 claims |
| Johnson & JohnsonXarelto, Invokana | $74 | $97,027117 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $199 | $94,86588 claims |
| Boehringer IngelheimJardiance, Jentadueto Xr | $97 | $94,820113 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $91 | $83,861123 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $30 | $46,91588 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $27,06845 claims |
| NovartisEntresto | $39 | $22,80434 claims |
| MerckJanumet Xr | $205 | $13,06914 claims |
| AbbVieLinzess | $184 | $11,63121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Clarion
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.